NeuroSense’s PrimeC shows biomarker shifts in Alzheimer’s trial

NeuroSense Therapeutics Ltd. has reported that its experimental Alzheimer’s therapy PrimeC produced statistically significant reductions in multiple microRNAs associated with Alzheimer’s disease, according to the company. In plasma samples from its Phase 2b PARADIGM trial, PrimeC significantly reduced levels of miR-146a-5p (p = 0.007), miR-21-5p (p = 0.003), miR-let-7a-5p (p = 0.028) and miR-let-7e-5p (p […] The post NeuroSense’s PrimeC shows biomarker shifts in Alzheimer’s trial appeared first on Longevity.Technology.